24.4 C
Vientiane
Tuesday, August 26, 2025
spot_img
Home Blog Page 170

Xinhua Silk Road: British online content creator impressed by achievements of Chinese dairy giant Mengniu in desertification fight

BEIJING, Aug. 6, 2025 /PRNewswire/ — British online content creator Jack Forsdike witnessed achievements of Chinese dairy giant Mengniu in combating desertification during his recent visit to the Ulan Buh Desert in north China’s Inner Mongolia Autonomous Region. 

 

To fight desertification, Mengniu has transformed over 200 square kilometers of desert into green pasture in recent years, planting more than 97 million trees. The project demonstrates how Chinese enterprises make ESG efforts to better the environment around them.

In July, Jack toured the green pasture, which now provides forage grasses for cows at Mengniu’s world-leading organic raw milk production base.

Mengniu’s “grass to pasture to milk” organic system has been recognized by the UN Global Compact, the world’s largest corporate social responsibility initiative, as a world-class corporate carbon-neutrality roadmap.

Committed to green development, the dairy giant vows to peak carbon emissions by 2030 and achieve carbon neutrality by 2050 while continuing to deliver premium dairy products to the world.

Original link: https://en.imsilkroad.com/p/346988.html

Pfizer Romania recognized as a Best Place to Work for 2025


BUCHAREST, ROMANIA – Media OutReach Newswire – 6 August 2025 – Pfizer Romania has been officially certified as one of the Best Places to Work in Romania for 2025, a recognition that highlights its commitment to fostering a workplace culture grounded in integrity, inclusion, and employee empowerment.

The Best Places to Work program is a leading international certification that honors organizations providing exceptional employee experiences. The evaluation combines anonymous employee feedback with a comprehensive HR assessment, measuring areas such as leadership, culture, well-being, growth opportunities, and people practices.

A Workplace Defined by Purpose, Trust, and Inclusion

Pfizer Romania’s certification was driven by impressive scores across key dimensions of workplace culture. According to the internal employee survey:

  • Leadership & Trust
  • 94% of employees say leaders respect labor laws
  • 89% believe leaders act with integrity and ethics
  • 86% agree leadership communicates a clear and inspiring vision
  • Culture of Inclusion
  • 94% say differences (gender, ethnicity, age) do not affect how people are treated
  • 90% feel their ideas and opinions are respected
  • 91% say integrity is a shared value across teams
  • Managerial Support
  • 93% say their manager upholds ethical standards
  • 90% feel supported in health and well-being
  • 88% receive meaningful feedback to grow
  • Engagement & Purpose
  • 86% overall employee satisfaction
  • 86% align with Pfizer’s commitment to social responsibility
  • 83% rate HR practices as people-focused

Strong HR Practices Back the Recognition

In addition to the strong employee feedback, Pfizer Romania achieved impressive results in the HR assessment, which benchmarks the company’s practices against recognized global standards. The results reflect how closely Pfizer Romania’s approach aligns with best-in-class HR practices across multiple areas:

  • 94% alignment with best practices in people-focused HR policies
  • 90% alignment in leadership support and strategic direction
  • 89% alignment in employee engagement initiatives
  • 88% alignment in teamwork and cross-functional collaboration
  • 81% alignment with best practices in benefits programs
  • 73% alignment in compensation structures and fairness
  • 93% alignment in community involvement and corporate social responsibility, reinforcing Pfizer’s strong commitment to societal impact

Leadership Reflections

“Being recognized as a Best Place to Work reinforces our belief that a successful business starts with a strong culture,” said Mirela Iordan, General Manager of Pfizer Romania. “Our values — Courage, Equity, Excellence, and Joy — are not just words; they guide how we lead, collaborate, and deliver on our mission.”

Iulia-Rodica Mateescu, Senior Manager, People Experience, added: “We’re honored by this recognition. It reflects our ongoing efforts to create an environment where every team member feels heard, valued, and supported to grow.”
Hashtag: #BestPlacesToWork

The issuer is solely responsible for the content of this announcement.

About Pfizer Romania

Pfizer Romania, a subsidiary of Pfizer Inc., has been serving Romanian communities for over 30 years, delivering innovative medicines and vaccines across multiple therapeutic areas. Guided by the global mission “Breakthroughs that change patients’ lives,” the company collaborates closely with healthcare providers and institutions to expand access to quality healthcare and advance public health outcomes.

About the Best Places to Work Program

Best Places to Work is a global HR certification program that identifies leading employers around the world. The certification process includes a rigorous evaluation of workplace culture through employee surveys and an audit of HR practices across eight key areas, including leadership, well-being, inclusion, and career development.

Learn more at:
LinkedIn:

Shamal Holding Unveils Naïa Island Dubai

A Private Estate Setting New Standards in Ultra-Luxury Living

DUBAI, UAE, Aug. 6, 2025 /PRNewswire/ — Shamal Holding, the Dubai-based diversified investment firm, today unveils Naïa Island Dubai – a landmark private estate set to redefine ultra-luxury living in the region.

Naïa Island Dubai Location
Naïa Island Dubai Location

 

At its heart, the island will host the region’s first Cheval Blanc maison, a defining moment for hospitality in the region. The maison will feature an intimate collection of suites and private villas, designed in Cheval Blanc’s distinctive style: contemporary, serene, and emotional luxury. A limited number of branded beachfront residences and estate plots will be available, each with private beach access offering a rare opportunity to reside on an island where design, nature, and lifestyle exist together perfectly.

Located just off Jumeirah’s coastline and seamlessly connected to Dubai’s principal roadways, Naïa Island Dubai has been designed as a resort masterplan shaped around open green spaces and coastal terrain. Its low-lying architecture offers unparalleled views of Dubai’s iconic landmarks, beautifully framed by the open sea. It is intended to provide residents and guests with the ultimate sense of exclusivity, privacy, and natural beauty.

Every amenity is designed to foster a connection with nature and a strong sense of place. From dining experiences to spa and wellness offerings, and a private marina, each element is thoughtfully integrated to flow with the island’s rhythm, grounding residents and guests in the surrounding landscape.

“This marks a defining chapter in our vision to create meaningful experiences, and an exciting step forward for Shamal as we continue to curate pioneering firsts that reinforce Dubai’s position as a global benchmark for exceptional, world-class living” said Abdulla Binhabtoor, CEO of Shamal Holding, “Naïa Island Dubai offers an enduring address, one that invites presence and lives beautifully overtime.”

With early works now underway, Naïa Island Dubai is poised to become one of the region’s most exclusive coastal addresses, a timeless setting reserved for a discerning few.

About Shamal

Born in Dubai, Shamal is a diversified investment firm that cultivates the extraordinary, through a unique portfolio of investments, experiences and assets. The investments we make are strategically chosen and thoughtfully nurtured, mirroring Dubai’s ambition, spirit, and energy.

Our real estate portfolio spans master communities, districts, residences, retail hubs and commercial spaces, we help realise potential, delivering unique developments such as Dubai Harbour and Nad Al Sheba Gardens. We invest in a range of properties, franchises and operations across the hospitality sector from luxury, premium and affordable experiences, with extraordinary domestic and international brands as diverse as Jumeirah Zabeel Saray, Hart Shoreditch Hotel London, Baccarat Hotel & Residences Dubai, SUSHISAMBA and Five Guys. As the owning company of some of Dubai’s most unique and iconic leisure and entertainment destinations, we curate extraordinary experiences every day. We also partner with best-in-class asset managers to manage a globally diversified investment portfolio.

For more information visit www.shamal.com
Shamal LinkedIn: @shamalholding 
Shamal IG: @shamalholding

Shamal Holding Unveils Naïa Island Dubai
Shamal Holding Unveils Naïa Island Dubai

 

Shamal Holding Unveils Naïa Island Dubai
Shamal Holding Unveils Naïa Island Dubai

 

ACEN earns top ESG recognitions from FTSE4Good Index and MSCI

MAKATI CITY, Philippines , Aug. 6, 2025 /PRNewswire/ — ACEN, the listed renewable energy platform of the Ayala Group, continues to demonstrate ESG leadership, securing recognition from two of the world’s leading Environmental, Social and Governance (ESG) rating agencies: FTSE Russell and MSCI. These recognitions reflect ACEN’s ongoing commitment to embed sustainability at the heart of its strategy, anchored on environmental stewardship, social responsibility, and sound corporate governance.

ACEN has once again retained its place in the FTSE4Good Index Series for the third year in a row, underscoring the company’s consistent performance in implementing best-in-class ESG practices.

Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indexes are used by a wide variety of market participants to create and assess responsible investment funds and other products.

FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change.  Businesses included in the FTSE4Good Index Series meet a variety of environmental, social and governance criteria.

ACEN joins fellow Ayala companies in the 2025 FTSE4Good list—Ayala Corporation (since 2016), Globe and Ayala Land (since 2015), and BPI (since 2020)—reaffirming the Ayala Group’s long-standing commitment to global sustainability standards.

In 2025, ACEN also received a rating of A (on a scale of AAA-CCC) in the MSCI ESG Ratings assessment, recognizing the company’s improved management of financially material sustainability risks and opportunities, especially within the energy sector.

MSCI ESG Ratings evaluate a company’s exposure to ESG risks and how well it manages them relative to industry peers. Ratings range from AAA (leader) to CCC (laggard), using a rules-based methodology to identify ESG leaders within each sector.

At ACEN, sustainability is more than a responsibility, it’s a strategic lever for growth. The company believes that sustainability delivers real business outcomes, driving performance across its operations and partnerships.

Jonathan Back, ACEN Chief Financial Officer and Chief Strategy Officer, said:  “ESG is embedded in how we invest, operate and grow. These upgraded ratings reflect the strength of our decarbonization strategy and our ability to manage sustainability risks while creating long-term value. As we expand across the region, ESG remains central to building capital efficiency, investor confidence and resilient growth.”

About ACEN

ACEN (PSE:ACEN), the Ayala group’s listed energy platform, is one of the fastest-growing renewable energy platforms in Asia Pacific, with the Philippines as its core and largest market. It also has a significant presence in Australia, Vietnam, India, and Lao PDR, along with strategic investments in Indonesia and other markets. The company currently has ~7 GW of attributable renewable energy capacity spanning operational, under-construction, and committed projects.

As a developer, builder, and operator, ACEN leverages its agility and collaborative approach to accelerate the energy transition. Committed to unlocking access to clean, reliable, and affordable renewable energy, the company is on track to achieve 100% renewable energy generation by 2025 and reach Net Zero greenhouse gas emissions by 2050—turning bold ambitions into real impact for businesses, communities, and indigenous groups.

www.acenrenewables.com

FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)

  • Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1]
  • AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19) in IV formulation [1]

INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ — Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA® IV in the United States.[1]

Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19).[1]

CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure.[2]

“We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas.”

In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential.

Notes to Editors:

About AVTOZMA® (CT-P47, tocilizumab-anoh)

AVTOZMA® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively.  

INDICATION 

AVTOZMA® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of:

  • Rheumatoid Arthritis (RA): Adult patients with moderately to severely active RA who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
  • Giant Cell Arteritis (GCA): Adult patients with GCA.
  • Polyarticular Juvenile Idiopathic Arthritis (pJIA): Patients 2+ years-old with active pJIA.
  • Systemic Juvenile Idiopathic Arthritis (sJIA): Patients 2+ years-old with active sJIA.
  • Cytokine Release Syndrome (CRS): Adults and pediatric patients 2+ years-old with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.
  • COVID-19: Hospitalized adult patients with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS INFECTIONS

AVTOZMA® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants.

If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include:

  • Active tuberculosis (TB) which may present with pulmonary or extrapulmonary disease. Test for latent TB before and during treatment (except in COVID-19 patients) and treat latent infections before starting AVTOZMA.
  • Invasive fungal infections: Such as candidiasis, aspergillosis, and pneumocystis, may present as disseminated rather than localized disease.
  • Opportunistic infections, including bacterial, viral and other opportunistic pathogens.

Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment.
Contraindications:
 Known hypersensitivity to tocilizumab products.
Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled.

Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management.

Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop.

Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts.

Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant.

Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity.

Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders.

Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended.

Live Vaccines. Avoid concurrent use with AVTOZMA.

Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), STEQEYMA® (ustekinumab-stba), and AVTOZMA® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA® (infliximab-dyyb). For more information, please visit https://www.celltrion.com/en-us.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, “anticipates”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

AVTOZMA® is a registered trademark of Celltrion Inc.
ACTEMRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd. 

References

[1]  AVTOZMA U.S. prescribing information (2025)

[2] International Myeloma Foundation. What is Cytokine Release Syndrome (CRS)? Available at: https://www.myeloma.org/managing-complications-side-effects/cytokine-release-syndrome-crs

For further information please contact:
Andria Arena
aarena@jpa.com
+1 516-578-0057

HR Path Strengthens Global Presence with Strategic Acquisition of PredictiveHR

PARIS, Aug. 6, 2025 /PRNewswire/ — HR Path, a global leader in HR consulting and HRIS solutions, is proud to announce its strategic acquisition of PredictiveHR, a U.S.-based company renowned for its deep expertise in HRIS advisory and implementation services, with a strong specialization in UKG solutions.

With a presence in 28 countries and a team of over 2,500 professionals, HR Path is a trusted partner for businesses navigating the complexities of Human Resources. Specializing in advisory, implementation, and operational services, HR Path delivers cutting-edge solutions designed to enhance efficiency and foster growth. Since it was founded in 2001, the company has stayed true to its mission of reshaping HR practices around the world.

Since 2016, PredictiveHR has been a trusted professional services partner for organizations leveraging HR technology platforms like UKG and Paylocity. With over a century of combined consulting experience, we specialize in implementation, optimization, and post-live support services that drive adoption, streamline operations, and deliver measurable results. PredictiveHR helps clients unlock the full potential of their HCM investments through strategic, hands-on expertise and white-glove service delivery.

This acquisition marks a significant milestone for HR Path, reinforcing its leadership in the HR industry and strengthening its footprint in the North American market. PredictiveHR’s dedicated focus on UKG implementation, post-go-live optimization, and managed services aligns seamlessly with HR Path’s vision of empowering organizational growth and excellence through strategic HR solutions.

“This is a powerful step forward in our mission to be the global reference in HR transformation,” said François Boulet, Co-founder of HR Path. “Their strong reputation in the North American market and deep expertise in UKG solutions enhance our ability to deliver high-value, end-to-end HR services worldwide. This partnership reflects our continued investment in innovation, client success, and global growth.”

“PredictiveHR brings a level of UKG expertise and service excellence that perfectly complements our global HRIS strategy,” said Theodore Smith, Partner at HR Path. “Together, we’re better positioned to support clients across North America and around the world with tailored, end-to-end UKG solutions that deliver measurable results.”

“We’re incredibly proud of what we’ve built at PredictiveHR,” said James Troiano, Founder and CEO. “From day one, our focus has been on delivering exceptional value through expertise, integrity, and innovation. Joining forces with HR Path allows us to expand that mission on a global scale, while staying true to the culture and client-first mindset that made us who we are. This acquisition is not just a milestone—it’s a launchpad for even greater impact.” 

PDF:   https://mma.prnewswire.com/media/2745259/HR_Path_EN.pdf

Contact : Fabienne LATOUR – Fabienne.latour@hr-path.com

Xencelabs Unveils Pen Display 24+: The Industry-first Drawing Display with Calman Ready Color Management Built-in

VANCOUVER, Wash., Aug. 6, 2025 /PRNewswire/ — Xencelabs, the brand dedicated to empowering artists with premium, best-in-class digital drawing tools, announced the Xencelabs Pen Display 24+ launch today. Designed as “A New Choice for Studio Creatives,” this groundbreaking display has Calman Ready color calibration technology built-in. This industry-first feature for pen displays will deliver unparalleled color accuracy and hardware-level calibration that enhances workflow efficiency in professional industries such as photography, illustration, animation, visual effects, filming, gaming, industrial design, and other color accuracy-critical creative fields.


An Industry First from Xencelabs
To address the need for color accuracy in the digital age, and requests from Xencelabs users, the Pen Display 24+ prioritizes color management for creative professionals who use drawing displays. Developed in collaboration with Portrait Displays, the built-in Calman Ready solution enables hardware-level calibration directly on the display. By storing calibration data (e.g., LUTs) on-device, artists achieve consistent, Hollywood-grade color fidelity across devices and workflows at all times.

Studio-Grade Color Precision, Simplified 
The color calibration process is streamlined with automatic features: users connect a Portrait Display C6 HDR5000 or compatible colorimeter to Calman® Professional[1] software which can bypass complex OS-level adjustments and software interferences, ensuring true-to-life colors meeting standard such as Adobe RGB, DCI-P3, Rec. 709, Rec. 2020 and sRGB. In addition to the above color space support, the Pen Display 24+ also supports the Pantone®-validated palettes and SkinTone™-certified realism. With this newly updated compatibility, Xencelabs Pen Display 24+ makes a critical step forward for professional creators working at film studios, streaming giants, and design firms worldwide.

Beyond Color: A World-class, Premium Drawing Experience
The Pen Display 24 series provide thoughtful design and experience for every aspect of the creative journey:

  • Pen-on-Paper Feel: The Super AG Etching™ glass surface provides optimal tooth, mimicking paper texture while eliminating glare and reflections, even under bright studio lights.
  • Finely Tuned Pressure Curve: Developed with the feedback of 100+ professional artists, the finely tuned pressure curve (8,192 levels, 3g initial activation) captures nuances from delicate strokes to bold lines. Two included pens, the 3 Button Pen + Eraser v2 and Thin Pen + Eraser v2, offer customizable shortcuts and Felt and Standard nibs for tactile versatility. They are also compatible with Xencelabs’ v2 Pen Tablet Series.
  • 4K UHD Visual Immersion: A 23.8-inch 4K display (3840×2160) renders over 1.07 billion colors with 99% Adobe RGB, 93% DCI-P3, and 99% sRGB coverage.
  • Remote Work Flexibility: Support for HP Anyware® (Windows Only) and Parsec[2] enables secure remote workflows, ideal for teams working across town and across the globe.

Engineered for Productivity and Comfort
The Pen Display 24+ prioritizes uninterrupted creativity with a detail-oriented, ergonomic workflow:

  • Quick Keys Remote: The Quick Keys shortcut remote has an OLED screen and offers up to 44 application-specific shortcuts (8 keys × 5 sets + 4 dial modes), auto-switching between software like Photoshop and ZBrush.
  • Virtual Tablet Mode™: Control multiple monitors/displays as one seamless canvas using just the pen. Draw, drag, and interact across screens effortlessly. Customize overlay color, transparency, size, and position to perfectly fit different software workspaces, delivering a smarter, more personalized workflow.
  • Silent, Fanless Design: With a fanless design and high-conductivity metal backplate, the Pen Display 24+ stays cool to the touch while remaining virtually silent, so you can stay focused on creation.
  • Ergonomic Versatility: The included Tilt Stand (16°–72°) supports one-handed adjustments, while the optional Multi-Axis Stand enables rotation and positioning on the edge of the desk with Off-the-Desk Mode.

Everything You Need, Included
Every Pen Display 24+ includes two v2 Pens, Quick Keys remote, Tilt Stand, Pen Case, Bluetooth dongle, nibs, drawing glove, cleaning cloth, and all cables, eliminating the need to purchase additional accessories. Kensington MicroSaver® 2.0 Lock Slot on the Pen Display and Kensington NANO® Security Slot™ on the Quick Keys remote for extra protection against theft or loss.

Pricing and Availability
The Xencelabs Pen Display 24+ is available now for $1,899 USD. For specifications and regional purchasing, visit www.xencelabs.com

About Xencelabs
Founded in 2019 by industry veterans from animation, illustration, and industrial design, Xencelabs creates premium digital drawing tools for professionals worldwide. Sold in over 40 countries, its products empower artists to “Create What You Dream” through relentless innovation and artist-driven design. Subscribe to Xencelabs social account on social media and explore the advanced experiences that your creative work deserves. Visit to know more www.xencelabs.com

[1] Users need to purchase the Calman® Professional software (Calman Studio and Calman Ultimate) provided by Portrait Displays. For the software compatibility and usage, please refer to https://www.portrait.com/calman-ready/https://www.portrait.com/calman-professional/, and https://www.portrait.com/resource-center/meter-compatibility-in-calman/ .

[2] Check Home page | HP Anyware Support and Connect to Work or Games from Anywhere | Parsec for more information of software and the compatibility.

 

XCENA to Launch MX1 Computational Memory in October; Recognized for Innovation at FMS 2025

SANTA CLARA, Calif., Aug. 6, 2025 /PRNewswire/ — XCENA™, a South Korea–based startup, unveiled its first product, MX1 computational memory, this week at the Future of Memory and Storage (FMS) event. XCENA is displaying MX1 at FMS (booth #734) and will be offering working samples to select partners starting in October 2025. A production-ready version is planned for 2026.

XCENA Unveils MX1 Computational Memory, Its First Flagship Product, at FMS 2025
XCENA Unveils MX1 Computational Memory, Its First Flagship Product, at FMS 2025

CXL, The Foundation of MX1’s Architecture 

MX1 is the world’s first computational memory product supporting PCIe® 6.0 and Compute Express Link® (CXL®) 3.2, the latest version of CXL, an open standard enabling high-speed, low-latency communication between CPUs, memory, and accelerators. MX1 brings compute capabilities closer to the memory layer to overcome the limitations of traditional memory hierarchies. This reduces the overhead of moving large volumes of data between memory and the CPU and allows data to be processed near where it resides — an architectural shift that improves overall system performance and reduces total cost of ownership (TCO) in data centers. 

CXL introduces a more dynamic and flexible approach to system design. By supporting memory expansion, cache coherency, and direct memory access, the standard allows more efficient coordination across heterogeneous components. These capabilities form the foundation that MX1 builds on in order to scale data processing and reduce latency in demanding workloads. 

Under the Hood: How MX1 Works 

MX1 utilizes near-data processing, incorporating thousands of in-house RISC-V cores within the chip to handle computation near memory. This approach minimizes CPU involvement in data movement, accelerating tasks such as vector database operations, data analytics, and memory-intensive queries. 

MX1 provides SSD-backed memory expansion, delivering petabyte-scale capacity with minimal latency overhead. It also incorporates advanced reliability features and hardware-assisted compression to maximize usable capacity.

Software Support and Developer Integration 

To maximize the benefits of MX1, software support is essential. XCENA provides a fully-integrated software development kit (SDK) comprised of low-level drivers, runtime libraries, and supporting tools to help developers evaluate, prototype, and deploy MX1 with minimal integration effort.  

The software stack ensures compatibility with standard system environments and development workflows, enabling seamless adoption across data-intensive applications, from in-memory analytics to AI inference acceleration. 

As MX1 enters its proof-of-concept phase, XCENA invites developers, system architects, and partners to explore the new possibilities enabled by computational memory.  Together, the industry is moving one step closer to a more flexible and efficient performance computing paradigm. 

XCENA Wins Memory Innovation Award at FMS 2025 

This week, XCENA was awarded the “Most Innovative Memory Technology” award at FMS for its breakthrough innovation that addresses the “memory wall” in modern computing systems. The award marks the company’s second consecutive recognition at the event, following its selection as “Most Innovative Startup” in 2024. 

“Computational Memory represents an emerging architectural approach that aims to accelerate performance and efficiency, particularly for data-intensive tasks. It does this by minimizing data movement between processing and memory components,” said Jay Kramer, Chair of the Awards Program and President of Network Storage Advisors, Inc. “We are proud to recognize XCENA with MX1, the world’s first computational memory controller supporting CXL 3.X and enabling high-throughput acceleration for data intensive workloads like AI and analytics.”

FMS 2025 is currently taking place in Santa Clara, California, from August 5-7, bringing together global leaders in memory and storage technology. As an exhibitor, XCENA is showcasing MX1 in booth #734 and engaging with prospective partners, customers, and developers. 

About XCENA 
Founded in 2022, XCENA is a fabless semiconductor company developing intelligent memory solutions and data-centric computing architecture with a foundation built on Compute Express Link® (CXL®), an open coherent interconnect technology. The company focuses on improving performance and efficiency in data-intensive systems by pushing the boundaries of memory technology. To learn more about XCENA or its products, visit www.xcena.com and follow us on LinkedIn

Compute Express Link and CXL are trademarks of the CXL Consortium

Media Contact 
contact@xcena.com